Laboratory for Pharmacogenetics
Laboratory Head
Taisei MUSHIRODA (Ph.D.)
A combination of genetic variations and environmental differences defines unique human characteristics, including individual responsiveness (effectiveness and adverse reaction) to drugs. Among several types of genetic variation, single-nucleotide polymorphisms (SNPs) are the most abundant throughout the genome. SNPs have lately received much attention in biomedical fields, because some of them can influence the quality and/or the quantity of particular gene products, and thereby serve as markers of individual risk for adverse drug reactions or susceptibility to complex diseases. We expect the genomic approach, by exploiting an already large collection of SNPs and haplotype maps based on that collection, to revolutionize drug discovery and development, as well as the practice of medicine, within the next 5-10 years. Genetic variations in genes encoding proteins involved in drug metabolism, transport and response are of increasing importance for selecting particular drugs and an optimal dosages to provide the maximum effect and minimal adverse reactions for individual patients. The SNP-based approach makes us confident of achieving one of our goals, which is establishment of 'personalized medicine' that can provide the right drug at the appropriate dose for each individual patient.
- Identification of gene(s) associated with drug responses
- March 03,2010
- Adverse effects of anti-HIV drug depends on HLA-B gene type
- Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, Ikezawa Z, Iijima M, Shiohara T, Hashimoto K, Kamatani N, Nakamura Y.:
"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population"
Hum Mol Genet 20: 1034-41 (2011) - Cha PC, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N, Nakamura Y.:
"Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese"
Hum Mol Genet 19: 4735-44 (2010) - Kiyotani K, Mushiroda T, Hosono N, Tsunoda T, Kubo M, Aki F, Okazaki Y, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H.:
"Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response"
Pharmacogenet Genomics 20: 565-8 (2010) - Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H.:
"Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients"
J Clin Oncol 28: 1287-93 (2010) - Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, Kiertiburanakul S, Charoenyingwattana A, Komindr S, Thongnak C, Mushiroda T, Nakamura Y, Chantratita W, Sungkanuparph S.:
"Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen"
Clin Infect Dis 15: 597-604 (2010) - Cha PC, Mushiroda T, Zembutsu H, Harada H, Shinoda N, Kawamoto S, Shimoyama R, Nishidate T, Furuhata T, Sasaki K, Hirata K, Nakamura Y.:
"Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression"
J Hum Genet 54: 572-80 (2009) - International Warfarin Pharmacogenetics Consortium:
"Estimation of the warfarin dose with clinical and pharmacogenetic data"
N Engl J Med 360: 753-64 (2009) - Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Chantratita W, Nakamura Y.:
"HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients"
Pharmacogenet Genomics 19: 139-46 (2009) - Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y.:
"Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia"
Cancer Sci 99: 967-72 (2008) - Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, Kubo M, Nakamura Y, Zembutsu H.:
"Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients received adjuvant tamoxifen therapy"
Cancer Sci 99: 995-9 (2008)
- Taisei MUSHIRODA
- Laboratory Head
- Takeshi OZEKI